BLEEDING;
CANCER CELL LINE;
CANCER CHEMOTHERAPY;
CANCER INCIDENCE;
CANCER SURVIVAL;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
EDITORIAL;
HUMAN;
LUNG HEMORRHAGE;
NON SMALL CELL LUNG CANCER;
PRIORITY JOURNAL;
CARCINOMA, NON-SMALL-CELL LUNG;
FEMALE;
LUNG NEOPLASMS;
MALE;
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma nonsmall-cell lung cancer
Scagliotti GV, Bondarenko I, Blackhall F et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma nonsmall-cell lung cancer. Ann Oncol 2015; 26: 497-504.
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-2619.
Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination
Nicholson RI, Hutcheson IR, Knowlden JM et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004; 10(1 Pt 2): 346S-354S.
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib
Morgillo F, Woo JK, Kim ES et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66: 10100-10111.
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
Rekhtman N, Paik P, Arcila ME et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012; 18: 1167-1176.
http://www.biotechnologyevents.com/node/5753 (30 November 2014, date last accessed).
8
84904679830
Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial
A#8000
Spigel DR, Edelman MJ, O'Byrne K et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014; 32 (5 suppl): A#8000.
Randomized phase III placebocontrolled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
Lara PN, Jr, Douillard J-Y, Nakagawa K et al. Randomized phase III placebocontrolled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2965-2971.
